Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)
Sponsor: Baylor College of Medicine
A PHASE1 clinical study on Liposarcoma and Liver Cancer, this trial is actively recruiting participants. The trial is conducted by Baylor College of Medicine and has accumulated 11 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE1
-
Oct 2024 — Jun 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
▶ Show 6 earlier versions
-
Mar 2024 — Jun 2024 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2022 — Aug 2023 [monthly]
Not Yet Recruiting PHASE1
-
Dec 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .